Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

[1] Ciardiello F(2008)EGFR antagonists in cancer treatment N Engl J Med 358 1160-74

[2] Tortora G(2001)Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127-37

[3] Yarden Y(2001)The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma Int J Gynecol Cancer 11 119-29

[4] Sliwkowski MX(1997)EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients Anticancer Res 17 613-9

[5] Skirnisdóttir I(1991)Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer Am J Obstet Gynecol 164 669-74

[6] Sorbe B(1999)Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer Anticancer Res 19 4469-74

[7] Seidal T(2004)Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group) Br J Cancer 91 470-5

[8] Fischer-Colbrie J(2005)Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study Int J Gynecol Cancer 15 785-92

[9] Witt A(2010)Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment Gynecol Oncol 119 451-6

[10] Heinzl H(2010)A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149) Gynecol Oncol 118 308-12

[1] Ciardiello F(2008)EGFR antagonists in cancer treatment N Engl J Med 358 1160-74

[2] Tortora G(2001)Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127-37

[3] Yarden Y(2001)The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma Int J Gynecol Cancer 11 119-29

[4] Sliwkowski MX(1997)EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients Anticancer Res 17 613-9

[5] Skirnisdóttir I(1991)Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer Am J Obstet Gynecol 164 669-74

[6] Sorbe B(1999)Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer Anticancer Res 19 4469-74

[7] Seidal T(2004)Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group) Br J Cancer 91 470-5

[8] Fischer-Colbrie J(2005)Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study Int J Gynecol Cancer 15 785-92

[9] Witt A(2010)Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment Gynecol Oncol 119 451-6

[10] Heinzl H(2010)A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149) Gynecol Oncol 118 308-12